Technology and life sciences companies continued to go public at an extraordinary rate in the first half of 2021 via initial public offerings, de-SPAC mergers and direct listings.

**IPOs**

IPOs outpaced the second half of 2020, which was previously the most active six months for the space since we began tracking in 2012. In H1 2021, there were 76 technology and 66 life sciences company IPOs in the U.S., compared to 48 and 65 in the second half of 2020, respectively.

With 32 IPOs in Q1 and 44 in Q2, technology IPO momentum built throughout the first half of the year. Life sciences offerings increased slightly throughout the first half of the year, with 31 IPOs in Q1 and 35 in Q2, still by far exceeding H1 2020 and several prior years’ offerings.

Mega offerings marked the first half of the year, with 17 companies raising proceeds of more than $1 billion, including one life sciences IPO. Technology IPOs saw deal sizes increase generally. Approximately 93% of IPOs raised more than $100 million in the first half of 2021, versus only 83% in the second half of 2020. Almost 21% of tech IPOs raised more than $1 billion in H1, the same as the second half of 2020.

The pace and size of technology companies going public in the first half of the year was representative of the fervent interest in the sector and robust market conditions. We expect activity levels to remain high for the rest of the year and into next year as companies have the option to go public through a variety of different ways including IPOs, SPACs and direct listings.

**Corporate Partner Ran Ben-Tzur**
We saw life sciences deals trend larger in terms of aggregate deal size compared to the second half of 2020. In the first half of 2021, more than 83% of life sciences IPOs raised $100 million or more, compared to approximately 77% of deals raising $100 million or more in the second half of 2020.

Nearly all of the IPOs in the first half of 2021 priced within or above-range—93% of technology offerings (down from 96% in the second half of 2020) and 94% of life sciences offerings (equal to the second half of 2020, also 94%)—indicating a continued strong market environment.

de-SPAC Mergers and SPAC IPOs

The de-SPAC (special purpose acquisition company) merger surge also continued: the number of tech and life sciences companies to go public via SPAC merger in the first half of 2021 increased 71 percent from the second half of 2020, and the number of life sciences de-SPAC transactions quadrupled. The 53 technology and life sciences de-SPAC mergers that closed in H1 by far exceeded the H2 2020 total of 31.

The number of SPAC IPOs continued to increase significantly in the first half of 2021, continuing a bullish streak. There were 362 across industries in H1 2021, versus the 247 in all of 2020 and 59 in all of 2019.

Direct Listings

The four direct listings in H1 2021 were double the number in the previous half year. They included Fenwick client Coinbase Global’s blockbuster Nasdaq direct listing which debuted on April 14, 2021, with the second largest market capitalization of any technology company ever at the time of its opening trade ($100 billion). Roblox Corporation, Squarespace and Fenwick client ZipRecruiter also completed direct listings in H1.

Outlook

The going public window was wide open in the first half of 2021 and July showed few signs of slowing down. The markets are showing resilience against the impact of the COVID-19 Delta variance and other challenges.

Despite the Delta variant likely impacting businesses and the economy on some level for the near term, we anticipate deal activity among technology and life sciences companies through the rest of 2021 to remain strong. We believe de-SPAC mergers and direct listings will continue to be an attractive way to go public, in addition to traditional IPOs, as companies weigh which option is best for them.

Life sciences companies are continuing to go public at a pace on track with last year, still by far exceeding many prior years as investor interest remains steady and the bull market continues.

Corporate Partner Robert Freedman
SPAC IPOs and de-SPAC Mergers

This graph shows the total number of SPAC IPOs completed since 2016.

SPAC IPOs 2016 – 2021 H1

This graph shows the total number of U.S. and foreign technology sector de-SPAC mergers that closed in H1 2021 and H2 2020.

TECHNOLOGY DE-SPAC Mergers

<table>
<thead>
<tr>
<th></th>
<th>H1 2021</th>
<th>H2 2020</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>37</td>
<td>27</td>
</tr>
</tbody>
</table>

This graph shows the total number of U.S. and foreign life sciences sector de-SPAC mergers that closed in H1 2021 and H2 2020.

LIFE SCIENCES DE-SPAC Mergers

<table>
<thead>
<tr>
<th></th>
<th>H1 2021</th>
<th>H2 2020</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>16</td>
<td>4</td>
</tr>
</tbody>
</table>
This graph shows the number of technology and life sciences IPOs completed during each quarter of 2012 through 2021 H1.

**IPOs Completed**

**NUMBER OF U.S. IPOS IN 2021 H1**

- **76 TECH**
  - 27 FOREIGN ISSUERS
  - 49 UNITED STATES

- **66 LIFE SCIENCES**
  - 16 FOREIGN ISSUERS
  - 50 UNITED STATES

**NUMBER OF U.S. IPOS IN 2021 H1**

- **TECH**
  - 66

- **LIFE SCIENCES**
  - 76

**Life Sciences—Foreign**

**Technology—Foreign**

**Life Sciences—U.S.**

**Technology—U.S.**

**Foreign Issuers**

**United States**

**IPOS PER QUARTER 2012 – 2021 H1**
The following scatter graphs plot the size of technology and life sciences IPOs completed during the first half of 2021 and second half of 2020 based on the actual public offering price per share and number of shares offered.
Aggregate Amount Raised, Final IPO Price

Technology Deal Size Distribution

Life Sciences Deal Size Distribution

The following graphs provide information about aggregate deal size based on the actual pricing of the offering in the first half of 2021 and second half of 2020.
IPO Pricing

The two graphs on the left show the percentage of technology and life sciences IPOs with a final price that falls above, within or below the estimated price range reflected in the preliminary prospectus in the first half of 2021 and second half of 2020. The two graphs on the right show the percentage of technology and life sciences deals that closed up, down or flat on their first day of trading in the first half of 2021 and second half of 2020.

RELATION OF FINAL IPO PRICE TO MIDPOINT OF ESTIMATED PRICE RANGE (% OF DEALS) 2020, SECOND HALF

RELATION OF FINAL IPO PRICE TO MIDPOINT OF ESTIMATED PRICE RANGE (% OF DEALS) 2021, FIRST HALF

RELATION OF PRICE AT 1ST DAY CLOSE TO FINAL IPO PRICE (% OF DEALS) 2020, SECOND HALF

RELATION OF PRICE AT 1ST DAY CLOSE TO FINAL IPO PRICE (% OF DEALS) 2021, FIRST HALF

<table>
<thead>
<tr>
<th>Category</th>
<th>Technology</th>
<th>Life Sciences</th>
<th>Technology</th>
<th>Life Sciences</th>
<th>Technology</th>
</tr>
</thead>
<tbody>
<tr>
<td>Above Range</td>
<td>41.7%</td>
<td>16.7%</td>
<td>51.3%</td>
<td>3.1%</td>
<td>4.2%</td>
</tr>
<tr>
<td>Within Range</td>
<td>77.3%</td>
<td>77.3%</td>
<td>25.0%</td>
<td>21.2%</td>
<td>18.5%</td>
</tr>
<tr>
<td>Below Range</td>
<td>4.2%</td>
<td>6.1%</td>
<td>7.9%</td>
<td>21.2%</td>
<td>18.4%</td>
</tr>
</tbody>
</table>

Life Sciences

Technology

Deals

Above Range

Within Range

Below Range

Closed Up

Closed Flat

Closed Down

Closed Up

Closed Flat

Closed Down

80.3%

77.3%

70.8%

78.5%

6.2%

4.2%

7.9%

6.1%

18.4%

1.3%

1.5%

21.2%
Price Changes Between the Estimated and Actual IPO Price

Estimating the offering price for the IPO in the preliminary prospectus and pricing the IPO upon completion of marketing efforts are processes that are equal parts science and art. These graphs show the median and average prices for technology and life sciences IPOs from the midpoint of the estimated price range reflected in the preliminary prospectus to the actual public offering price to the closing price on the first day of trading, for the first half of 2021 and second half of 2020.

AVERAGE PRICES FOR TECHNOLOGY & LIFE SCIENCES IPO DEALS

2021 H1
2020 H2

Technology

Life Sciences

MEDIAN PRICES FOR TECHNOLOGY & LIFE SCIENCES IPO DEALS
Authors

James D. Evans  
Co-Chair  
Capital Markets & Public Companies  
jevans@fenwick.com  
Full Bio

Robert A. Freedman  
Co-Chair  
Capital Markets & Public Companies  
rfreedman@fenwick.com  
Full Bio

Amanda L. Rose  
Partner  
Capital Markets & Public Companies  
arose@fenwick.com  
Full Bio

Ran D. Ben-Tzur  
Partner  
Capital Markets & Public Companies  
rbentzur@fenwick.com  
Full Bio

Fenwick’s Capital Markets Team

As leaders in the technology and life sciences industries for the past 50+ years, Fenwick’s capital markets team is consistently a key player in some of the most high-profile IPOs and equity offerings. Our continued success guiding market leaders has ranked the group in 2021 as #1 issuer-side for public offerings by deal value, according to Deal Point Data. The group was also named Capital Markets Group of the Year by Law360 in 2019 and recognized nationally for capital markets in Chambers USA and Legal 500 in 2021.

Other Members of Fenwick’s Capital Markets Team

Per Chilstrom  
Partner  
Capital Markets & Public Companies  
pchilstrom@fenwick.com  
Full Bio

Katherine K. Duncan  
Partner  
Capital Markets & Public Companies  
kduncan@fenwick.com  
Full Bio

Julia Forbess  
Partner  
Capital Markets & Public Companies  
jforbess@fenwick.com  
Full Bio

Michael Pilo  
Partner  
Capital Markets & Public Companies  
mpilo@fenwick.com  
Full Bio

Aman Singh  
Partner  
Capital Markets & Public Companies  
asingh@fenwick.com  
Full Bio

Contact the authors or members of your client service team to discuss the report or for more information.
Methodology

Data points used in the compilation and analysis of this information were gathered using a variety of resources, including, but not limited to, filings made with the U.S. Securities and Exchange Commission, lock-up expiration dates from EDGAR Online IPO Deal Data and daily stock-trading price data. The exact dates upon which lock-ups expired were estimated based on disclosure in the prospectuses and may further be approximate in the case of dates falling on holidays or weekends. Companies were assigned to the Technology and Life Sciences sectors based on SIC codes and other company descriptors.

The information in the graphs and tables regarding offering size does not reflect any exercise of the underwriters’ over-allotment, or green shoe, option. Information at the preliminary prospectus stage is based on the midpoint of the range and on the number of shares offered, as reflected on the cover page of the first preliminary, or red herring, prospectus. The information regarding the actual offering size is based on the price to the public and the aggregate number of shares offered, as reflected on the cover page of the final prospectus. The closing price on the first day of trading is the closing price on the company’s primary exchange on the first day of public trading of the shares following the pricing of the offering.

Disclaimer

The preparation of the information contained herein involves assumptions, compilations and analysis, and there can be no assurance that the information provided herein is error-free. Neither Fenwick & West LLP nor any of its partners, associates, staff or agents shall have any liability for any information contained herein, including any errors or incompleteness. The contents of this report are not intended, and should not be considered, as legal advice or opinion.

Sign-Up Information

To be placed on an email list for future editions of this survey, please visit fenwick.com/iposurvey and go to the sign-up link at the bottom of the page.

© 2021 Fenwick & West LLP